Ilika CEO on Stereax sales and Goliath battery progress

Ilika has resumed commercial deliveries of its Stereax batteries after completing a technology transfer to Cirtec Medical in the US and booked its first follow-on commercial electrode order (UK-manufactured) that will generate revenue. Its Goliath solid‑state cells have completed customer validation at both 2Ah and scaled 10Ah sizes, with 10Ah units now with OEMs/Tier Ones and claimed pack-level benefits of roughly £2,500 (~$3,000) savings, ~20% weight reduction and faster charge times (18 to 12 minutes). Management is focused on further validation, agreeing minimum viable products (potentially at 10Ah), freezing designs and scaling manufacturing via partners while modest revenues and grant funding continue to support development.

Analysis

Market structure: Ilika’s resumed Stereax shipments and validated 2Ah→10Ah Goliath cells create near-term winners (Ilika: AIM:IKA / OTCQX:ILIKF, Cirtec) and potential medium-term disruption for incumbents in large-format Li‑ion pack suppliers. The quoted pack-level saving (~£2,500 / $3,000) and ~20% weight reduction imply meaningful pricing pressure on legacy cell makers if scaleable; realistic automotive adoption is 2–5 years, not immediate. Commodity demand shifts (nickel/cobalt) would be modest short-term but could reduce marginal demand over multi-year horizons if solid‑state chemistries displace high-Ni cathodes at scale.

Risk assessment: Key tail risks are (1) manufacturing transfer failures (Cirtec scale issues), (2) customer validation reversal at pack/module integration, (3) necessity of dilutive capital raises, and (4) regulatory/qualification setbacks for medical Stereax or EV safety rules. Immediate horizon (days) sees limited market reaction; short-term (3–12 months) hinges on 10Ah customer MVPA/first module orders; long-term (12–36 months) depends on 50Ah scale and OEM commitments. Hidden dependencies include retained UK electrode capacity, grant funding (PRIMED) continuity, and concentration of Tier‑One partners.

Trade implications: Tactical exposure to Ilika is high-reward/high-risk: establish small asymmetric positions now (1–2% portfolio) with milestone-based scaling (see decisions). Relative-value: long near-term commercialisers (Ilika) vs short long‑horizon hype names (QuantumScape QS, Solid Power SLDP) where timelines remain uncertain. Cross-asset: consider modest long exposure to specialty electrode/materials suppliers and underweight miners if confirmation of SSB adoption occurs over 24–36 months.

Contrarian angles: Consensus likely underestimates scale‑up friction and capital intensity—10Ah validation ≠ mass production; downside (dilution, failed transfer) is underpriced in small‑cap Ilika. Conversely, market may be underreacting to first recurring revenues (electrodes order) and a completed US transfer; a disciplined milestone-driven re-rating (MVPA, first pack order, £2–5m revenue run‑rate) could produce outsized returns versus peers priced for multi-year binary outcomes.

Key Decisions for Investors

• Establish a tactical long position in Ilika (AIM:IKA or OTCQX:ILIKF) sized 1–2% of portfolio immediately. If Ilika signs a 10Ah MVPA or reports consecutive quarterly Stereax revenue ≥£2–3m within 6 months, increase to 3–5% and trim half at a 2.5x return or if a capital raise >£10m is announced.
• Implement a relative‑value pair: long IKA (as above) vs short QuantumScape (NYSE:QS) or Solid Power (NASDAQ:SLDP) sized 0.5–1% portfolio notional on the short side. Use 9–12 month put options ~25–35% OTM on QS/SLDP if available (prefer puts to naked short) to express conviction that near-term commercialization will diverge.
• Buy downside protection on this thematic exposure: purchase 9–12 month puts on QS/SLDP (~25–35% OTM) sized to cover 0.5–1% portfolio risk, or if liquid options on ILIKF exist, buy a 12 month out‑of‑the‑money call spread (defined risk) instead of outright stock increase.
• Reduce 1–2% exposure to large incumbent battery/cathode names or miners with >50% revenue tied to high‑Ni chemistries if, over the next 12 months, Ilika/peer solid‑state developers announce multiple OEM module orders; redeploy into specialty electrode/component suppliers and UK battery industrialisation partners showing confirmed supply agreements.
• Set hard monitoring triggers: if Ilika announces (a) failure of tech transfer or missed delivery commitments, (b) cash runway <12 months or planned dilutive raise, or (c) loss of PRIMED funding, exit long positions entirely within 5 trading days.